HC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $11.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a Buy rating on Innate Pharma (NASDAQ:IPHA) and maintained a price target of $11.5.
November 15, 2023 | 1:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst reaffirms a Buy rating on Innate Pharma with a price target of $11.5.
The reiteration of a Buy rating and the maintenance of a price target by a reputable analyst can lead to increased investor confidence and a potential short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100